Axon Enterprise (AXON) Earnings Date & Reports

Key Takeaways

• Revenue reached $904.3 million in Q2 2026, up 35% year over year and marking the company's tenth consecutive quarter of growth above 30%.
• Adjusted earnings per share (EPS) came in at $1.88, beating consensus estimates of $1.83 by $0.05, while revenue exceeded forecasts by roughly $28 million.
• Full-year revenue guidance was raised to 32%–34% growth, up from the prior range of 30%–32%, though adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) margin guidance remained at approximately 25.5%.
• Shares fell 6.52% in after-hours trading to $569.77 despite the headline beat, as investors focused on near-term margin pressure, limited free cash flow, and elevated valuation.
• Annual recurring revenue (ARR) surged 39% to $1.64 billion, and future contracted bookings climbed more than 40% to $15.1 billion, signaling durable demand momentum.

Earnings Context and Why It Matters

Axon Enterprise's Q2 2026 results arrive at a pivotal moment. The company, best known for its TASER devices, body cameras, and cloud-based software platform for public safety, has transformed into a technology ecosystem serving law enforcement, federal agencies, enterprises, and international customers across more than 85 countries. With shares trading at a premium valuation of roughly 244 times trailing earnings and the stock still down approximately 29% over the past 12 months, investors were laser-focused on whether Axon could sustain its breakneck expansion while improving profitability. This quarter offered a test: could the company keep delivering 30%-plus revenue growth for a tenth straight quarter while addressing lingering concerns around cash flow, margin execution, and the pace at which newer product lines contribute to the bottom line?

Reported Results

Axon delivered another quarter of impressive top-line expansion. Revenue of $904.3 million surpassed the consensus estimate of approximately $876 million and represented 35% growth compared to the same quarter a year ago. Software and Services revenue rose 36% to $398 million, while Connected Devices revenue increased 35% to $507 million. Within Connected Devices, Platform Solutions—which includes counter-drone offerings from the recently acquired Dedrone business—surged 123% to $150 million, exceeding analyst expectations of roughly $100 million. TASER revenue grew 21% to $261 million, and Personal Sensors revenue rose approximately 3% to $95 million.

Adjusted EPS of $1.88 edged past the consensus forecast of $1.83. Adjusted gross margin expanded 130 basis points sequentially to 62.9%, helped in part by a tariff refund benefit that is not expected to repeat in Q3. Adjusted EBITDA reached $242 million, translating to a 26.8% margin. Operating cash flow improved to $20 million from an outflow of $92 million a year earlier, though free cash flow was roughly breakeven at negative $1 million as the company continued investing in inventory to support demand and mitigate supply-chain risk. Management raised full-year revenue growth guidance to 32%–34% and maintained full-year adjusted EBITDA margin guidance at approximately 25.5%.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics, making it easier to identify trade ideas, trending stocks, breakout candidates, and market opportunities. For investors tracking high-growth technology names like Axon, tools such as the AI Screener can surface relevant opportunities across the broader defense technology and SaaS landscape more efficiently than manual screening alone.

Market Reaction and Investor Sentiment

Axon shares closed the regular session at $610.05, up modestly from the prior close, but fell sharply to $569.77 in after-hours trading—a drop of 6.52%, or approximately $40. The selloff underscored a disconnect between strong headline results and deeper investor unease. Management flagged that Q3 margins will face pressure from elevated memory component costs and the absence of the tariff refund that boosted Q2. Additionally, free cash flow remained constrained by inventory investment, and the stock's premium valuation—trading at over 200 times trailing earnings—leaves little room for execution missteps. The market appeared to interpret the report as confirmation that Axon's growth trajectory is intact but that the path to stronger cash generation and normalized margins may take longer than previously hoped.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors should pay close attention to several key themes that will shape Axon's trajectory through the remainder of 2026 and beyond.

First, margin recovery in the fourth quarter will be critical. Management expects adjusted EBITDA margins to face headwinds in Q3 due to higher memory component costs and the absence of a one-time tariff refund benefit, but projects a rebound in Q4 that should bring the full-year figure in line with the approximately 25.5% target. Whether the company can deliver on that timeline will heavily influence sentiment.

Second, the counter-drone business—driven by the Dedrone acquisition—has quickly become one of Axon's largest product lines, surpassing $100 million in quarterly revenue. Continued traction in this segment, including the company's participation in a $1.5 billion Department of Homeland Security counter-unmanned aircraft systems program, represents a significant catalyst but also introduces execution complexity as the business scales.

Third, international expansion and large contract wins remain central to the growth story. International bookings roughly tripled year over year in Q2, and the company signed several nine-figure domestic agreements. Sustaining this pace while managing longer and more varied contract durations will test Axon's operational discipline.

Finally, free cash flow generation warrants close monitoring. Management reaffirmed its expectation for $450 million in full-year free cash flow, implying substantial fourth-quarter seasonality. If inventory investment moderates as planned after this year, cash conversion could improve meaningfully, potentially easing one of the market's most persistent concerns.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations